Avelox Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Developing Operational Definitions Related to Helicobacter pylori Eradication Therapy
CONCLUSION: We developed and validated operational definitions related to H. pylori eradication therapy. These definitions will help researchers perform various H. pylori eradication-related studies using secondary databases.PMID:37667583 | PMC:PMC10477078 | DOI:10.3346/jkms.2023.38.e278 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - September 5, 2023 Category: Biomedical Science Authors: Chan Hyuk Park Sun-Young Jung Ju Won Lee Hyo-Joon Yang Joon Sung Kim Beom Jin Kim Soo In Choi Seung In Seo Joongyub Lee Jae Gyu Kim Korean Research Association for Helicobacter and Microbiome Source Type: research

Developing Operational Definitions Related to Helicobacter pylori Eradication Therapy
CONCLUSION: We developed and validated operational definitions related to H. pylori eradication therapy. These definitions will help researchers perform various H. pylori eradication-related studies using secondary databases.PMID:37667583 | PMC:PMC10477078 | DOI:10.3346/jkms.2023.38.e278 (Source: J Korean Med Sci)
Source: J Korean Med Sci - September 5, 2023 Category: General Medicine Authors: Chan Hyuk Park Sun-Young Jung Ju Won Lee Hyo-Joon Yang Joon Sung Kim Beom Jin Kim Soo In Choi Seung In Seo Joongyub Lee Jae Gyu Kim Korean Research Association for Helicobacter and Microbiome Source Type: research

Bilateral Acute Iris Transillumination Associated with Moxifloxacin Antibiotic Use
CONCLUSIONS: Our data support the notion that moxifloxacin might be associated with the onset of BAIT syndrome. Notably, within our cohort, two patients received moxifloxacin as surgical prophylaxis and subsequently developed BAIT syndrome. This could suggest a potential association between moxifloxacin and the onset of BAIT, though further studies are needed to confirm this finding.PMID:37652695 | DOI:10.1080/09273948.2023.2246543 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - August 31, 2023 Category: Allergy & Immunology Authors: Gabriela A Gorbea Fuxench Sof ía C Ayala Rodríguez Gabriel Guardiola Fabiola Ramos Mariella Pappaterra-Rodr íguez Guillermo A Requejo Figueroa Stephanie M Llop Luis A Santiago Carmen Santos Armando L Oliver Source Type: research

 Clostridioides difficile resistance to antibiotics, including post-COVID-19 data
Expert Rev Clin Pharmacol. 2023 Aug 29:1-14. doi: 10.1080/17512433.2023.2252331. Online ahead of print.ABSTRACTINTRODUCTION: Updating data on Clostridioides difficile antibiotic resistance is important for treatment improvement of C. difficile infections (CDIs).AREAS COVERED: Results from 20 countries were included. The mean resistance to 2 mg/l vancomycin, 2 mg/l metronidazole, 4 mg/l moxifloxacin, and 4 mg/l clindamycin was 4.7% (0 to ≥ 26% in two studies), 2.6% (0 to ≥ 40% in 3 studies), 34.9% (6.6->80%), and 61.0% (30->90%), respectively. Resistance to erythromycin (>60-88%), rifampin (>23-55.0%), imipe...
Source: Pharmacological Reviews - August 29, 2023 Category: Drugs & Pharmacology Authors: Lyudmila Boyanova Georgi Dimitrov Raina Gergova Petyo Hadzhiyski Rumyana Markovska Source Type: research

 Clostridioides difficile resistance to antibiotics, including post-COVID-19 data
Expert Rev Clin Pharmacol. 2023 Aug 29:1-14. doi: 10.1080/17512433.2023.2252331. Online ahead of print.ABSTRACTINTRODUCTION: Updating data on Clostridioides difficile antibiotic resistance is important for treatment improvement of C. difficile infections (CDIs).AREAS COVERED: Results from 20 countries were included. The mean resistance to 2 mg/l vancomycin, 2 mg/l metronidazole, 4 mg/l moxifloxacin, and 4 mg/l clindamycin was 4.7% (0 to ≥ 26% in two studies), 2.6% (0 to ≥ 40% in 3 studies), 34.9% (6.6->80%), and 61.0% (30->90%), respectively. Resistance to erythromycin (>60-88%), rifampin (>23-55.0%), imipe...
Source: Expert Review of Clinical Pharmacology - August 29, 2023 Category: Drugs & Pharmacology Authors: Lyudmila Boyanova Georgi Dimitrov Raina Gergova Petyo Hadzhiyski Rumyana Markovska Source Type: research